Proteolysis-targeting chimeras (PROTACs) hold therapeutic promise but face challenges of high molecular weight, polarity, and poor drug-like properties. Here, authors develop PLA-based SM-PROTACs that achieve efficient target degradation and superior low-dose, long-term tumor inhibition in vivo
- Mei-miao Zhan
- Hailing Chen
- Feng Yin